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Therapeutic use of immunoregulatory cells represents a promising approach for the
treatment of uncontrolled immunity. During the last decade, myeloid-derived
suppressor cells (MDSC) have emerged as novel key regulatory players in the context
of tumor growth, inflammation, transplantation or autoimmunity. Recently, MDSC
have been successfully generated in vitro from naive mouse bone marrow cells or
healthy human PBMCs using minimal cytokine combinations. In this study, we aimed
to evaluate the potential of adoptive transfer of such cells to control auto- and allo-
immunity in the mouse. Culture of bone marrow cells with GM-CSF and IL-6
consistently yielded a majority of CD11b+Gr1hi/lo cells exhibiting strong inhibition of
CD8+ T cell proliferation in vitro. However, adoptive transfer of these cells failed to
alter antigen-specific CD8+ T cell proliferation and cytotoxicity in vivo. Furthermore,
MDSC could not prevent the development of autoimmunity in a stringent model of
type 1 diabetes. Rather, loading the cells prior to injection with a pancreatic neo-
antigen peptide accelerated the development of the disease. Contrastingly, in a
model of skin transplantation, repeated injection of MDSC or single injection of LPS-
activated MDSC resulted in a significant prolongation of allograft survival. The
beneficial effect of MDSC infusions on skin graft survival was paradoxically not
explained by a decrease of donor-specific T cell response but associated with a
systemic over-activation of T cells and antigen presenting cells, prominently in the
spleen. Taken together, our results indicate that in vitro generated MDSC bear
therapeutic potential but will require additional in vitro factors or adjunct
immunosuppressive treatments to achieve safe and more robust immunomodulation
upon adoptive transfer.
URL de la
notice http://okina.univ-angers.fr/publications/ua9211 [10]
DOI 10.1371/journal.pone.0100013 [11]
Lien vers le
document http://dx.doi.org/10.1371/journal.pone.0100013 [11]
Liens
[1] http://okina.univ-angers.fr/publications?f[author]=16529
[2] http://okina.univ-angers.fr/publications?f[author]=16530
[3] http://okina.univ-angers.fr/publications?f[author]=16531
[4] http://okina.univ-angers.fr/publications?f[author]=16532
[5] http://okina.univ-angers.fr/publications?f[author]=16533
[6] http://okina.univ-angers.fr/publications?f[author]=16534
[7] http://okina.univ-angers.fr/publications?f[author]=3873
[8] http://okina.univ-angers.fr/publications?f[author]=16507
[9] http://okina.univ-angers.fr/publications?f[author]=16536
[10] http://okina.univ-angers.fr/publications/ua9211
[11] http://dx.doi.org/10.1371/journal.pone.0100013
Publié sur Okina (http://okina.univ-angers.fr)
